Merck, Daiichi Sankyo withdraw US application for lung cancer drug
25/09/2026 21:37
Merck, Daiichi Sankyo withdraw US application for lung cancer drug Sept 25 (Reuters) - Merck MRK.N and Daiichi Sankyo 4568.T have voluntarily withdrawn their US application seeking accelerated approval for their experimental lung cancer therapy, the drugmakers said on Friday.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Maju Samuel)
Recent news on Merck & Co
See all newsAbbVie's skin disease drug reduces lesions in trial, company eyes weight-loss combination
Factbox: Pharma sector doubles down on AI to slash costs, timelines
Brief: European Commission Approves Keytruda Plus Padcev As Perioperative Treatment For Adults With Resectable Muscle-Invasive Bladder Cancer
US STOCKS-Dow leads Wall Street higher, investors focus on healthcare stocks
Moderna recoups part of losses as BofA raises PO ahead of key cancer vaccine readout